Project Grant R21DA060345
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$432K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Binghamton, NY 13902, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $1,485,691 to Duke University to evaluate the neural correlates and behavioral impact of withdrawal-induced hyperalgesia (increased pain sensitivity) among people who smoke, with and without chronic pain. The key objectives are to: 1) Examine the impact of smoking withdrawal on brain fMRI responses to noxious heat stimuli, and 2) Investigate...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $241,500 to Duke University to examine the use of very low nicotine content (VLNC) cigarettes as a means to improve smoking cessation outcomes among individuals with opioid use disorder and chronic pain. The research will employ a randomized design to evaluate the effects of VLNC cigarettes versus normal nicotine content cigarettes on smoking...
The National Institute on Drug Abuse (NIDA) awarded a $770,751 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Oregon Health & Science University (OHSU) with a period of performance from July 1, 2025 to March 31, 2030. The grant supports research to examine the impact of telehealth expansion on access to and utilization of opioid use disorder (OUD) treatment within community health centers (CHCs). The study will use over 10 years of electronic health...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $146,922 to Indiana University to evaluate the association between general chronic pain liability and clinically recognized substance use. The project aims to clarify the underlying mechanisms linking chronic pain and substance use disorders, accounting for heterogeneity across and comorbidity among chronic pain conditions, as well as...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will pilot an innovative digital Contingency Management (CM) treatment delivered via mobile device to Medicaid beneficiaries with co-occurring opioid and alcohol use disorders. The $390,000 award, spanning from September 2024 to August 2027, aims to: 1) identify optimal approaches to engage Medicaid beneficiaries in digital CM through Medicaid claims data...
The National Institute on Drug Abuse (NIDA) awarded a $445,000 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The grant will fund the development and pilot testing of a novel telehealth and mobile health intervention called MOMENT-V to address cannabis use disorder in young adults seen in primary care. The intervention combines motivational enhancement therapy delivered via...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,870 to 2Morrow Inc. to accelerate the commercialization and dissemination of their evidence-based digital behavioral therapeutic for individuals with chronic pain. The funding will be used to hire a fractional Chief Commercial Officer (CCO) to review and validate 2Morrow's commercialization plan, and then execute a...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,930,360 to evaluate the real-world effectiveness of telehealth-delivered buprenorphine (tele-buprenorphine) for treating opioid use disorder (OUD). The study will use national data from the Veterans Health Administration and Medicaid to compare the effectiveness of tele-buprenorphine to in-person care, including for high-risk and high-need...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $118,457 to The Trustees of the University of Pennsylvania to conduct research aimed at harnessing the genetics of chronic pain to inform the development of non-addictive analgesic medications. The 4-year project, starting on April 15, 2025, will characterize the genetic architecture underlying chronic pain liability and addiction, estimate...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $844,475 to the University of Alabama at Birmingham (UAB) to test a bundled intervention aimed at increasing treatment uptake for patients with opioid use disorder (OUD) and nonfatal opioid overdoses after emergency department (ED) discharge. The proposed intervention combines telehealth, peer support, buprenorphine prescribing, and linkage to...